8-K
false 0001157601 0001157601 2020-06-17 2020-06-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): J une 17, 2020 (June 17, 2020)

 

MADRIGAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33277

 

04-3508648

(State or another jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

     

Four Tower Bridge

200 Barr Harbor Drive, Suite 200

West Conshohocken, Pennsylvania

 

19428

(Address of principal executive offices)

 

(Zip Code)

(267) 824-2827

Registrant’s telephone number, including area code

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 Par Value Per Share

 

MDGL

 

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) 2020 Annual Meeting of Stockholders

The Company held a virtual Annual Meeting, via Internet webcast, at 9:00 a.m., Eastern time, on Wednesday, June 17, 2020. As of April 24, 2020, the record date for the Annual Meeting, the Company had 15,429,154 shares of its common stock outstanding and entitled to vote, of which 14,339,286 shares of the Company’s common stock were present in person or represented by proxy and entitled to vote, constituting a quorum, at the Annual Meeting.

(b) Annual Meeting Voting Results

The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting. These matters are described in more detail in the Proxy Statement.

Proposal No. 1: The Company’s stockholders elected each of the three Class I nominees named below to serve on the Company’s Board of Directors for a three-year term expiring at the Company’s 2023 annual meeting of stockholders and until their respective successors are duly elected and qualified.

Class I Nominee

 

Votes For

   

Votes Withheld

   

Broker Non-votes

 

Paul A. Friedman, M.D.

   

11,237,483

     

680,239

     

2,421,564

 

Kenneth M. Bate

   

10,223,285

     

1,694,464

     

2,421,564

 

James M. Daly

   

10,197,153

     

1,720,569

     

2,421,564

 

Proposal No. 2: The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

14,334,506

 

4,175

 

605

 

—  

Proposal No. 3: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement.

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

11,799,778

 

93,291

 

24,653

 

2,421,564


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

MADRIGAL PHARMACEUTICALS, INC.

             

Date: June 18, 2020

 

 

 

/s/ Brian J. Lynch

 

 

 

Brian J. Lynch

 

 

 

Senior Vice President and General Counsel

v3.20.1
Document and Entity Information
Jun. 17, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001157601
Document Type 8-K
Document Period End Date Jun. 17, 2020
Entity Registrant Name MADRIGAL PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33277
Entity Tax Identification Number 04-3508648
Entity Address, Address Line One Four Tower Bridge
Entity Address, Address Line Two 200 Barr Harbor Drive
Entity Address, Address Line Three Suite 200
Entity Address, City or Town West Conshohocken
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19428
City Area Code (267)
Local Phone Number 824-2827
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 Par Value Per Share
Trading Symbol MDGL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false